Table 2.
Changes of clinical parameters after dapagliflozin treatment for 12 and 24 weeks
| Parameter | 12 Weeks | Change | P value | 24 Weeks | Change | P value |
|---|---|---|---|---|---|---|
| HbA1c, % (SD) | 7.5 (1.2) | − 0.6 (1.2) | < 0.001 | 7.2 (1.0) | − 0.8 (1.2) | < 0.001 |
| FPG, mg/dl (SD) | 139.6 (38.9) | − 26.6 (49.8) | < 0.001 | 133.9 (31.0) | − 27.0 (48.8) | < 0.001 |
| PPG, mg/dl (SD) | 189.9 (66.4) | − 43.1 (84.9) | < 0.001 | 172.1 (56.0) | − 51.6 (92.6) | < 0.001 |
| BMI, kg/m2(SD) | 27.6 (4.2) | − 0.9 (1.0) | < 0.001 | 27.6 (4.7) | − 1.0 (1.3) | < 0.001 |
| Weight, kg (SD) | 73.9 (14.4) | − 2.3 (2.6) | < 0.001 | 74.7 (16.0) | − 2.7 (3.6) | < 0.001 |
| SBP, mmHg (SD) | 125.8 (13.2) | − 3.1 (14.5) | < 0.001 | 123.2 (13.7) | − 2.3 (13.9) | < 0.001 |
| DBP, mmHg (SD) | 76.7 (9.8) | − 1.6 (10.2) | < 0.001 | 75.3 (10.3) | − 1.1 (10.6) | < 0.001 |
Data are presented as mean ± standard deviations
HbA1c glycated hemoglobin, FPG fasting plasma glucose, PPG postprandial glucose, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure